UroGen Pharma Ltd. SEC filings URGN
UroGen Pharma Ltd. has 583 filings in SEC EDGAR's recent list, going back to Mar 4, 2016. Its latest annual report, Form ARS, was filed on May 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 30, 2026 | Dec 31, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Jul 15, 2025 | Aug 11, 2025 |
| DEFA14A | Additional proxy material | Jul 1, 2024 | — |
| DEF 14A | Proxy statement | Jul 1, 2024 | Aug 7, 2024 |
| DEFA14A | Additional proxy material | Aug 1, 2023 | — |
| DEF 14A | Proxy statement | Aug 1, 2023 | Sep 7, 2023 |
| DEFA14A | Additional proxy material | May 17, 2022 | — |
| DEFA14A | Additional proxy material | May 2, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 8, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2021 | — |
| DEF 14A | Proxy statement | Apr 28, 2021 | Jun 7, 2021 |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Jun 8, 2020 |
| DEF 14A | Proxy statement | Apr 26, 2019 | Jun 3, 2019 |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- URGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ra'Anana, Israel
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1668243
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.